Chronic and juvenile myelomonocytic leukemias (CMML and JMML) are myelodysplastic/myeloproliferative neoplasia (MDS/MPN) overlap syndromes that respond poorly to conventional treatments. Aberrant Ras activation because of NRAS, KRAS, PTPN11, CBL and NF1 mutations is common in CMML and JMML. However, no mechanism-based treatments currently exist for cancers with any of these mutations. An alternative therapeutic strategy involves targeting Ras-regulated effector pathways that are aberrantly activated in CMML and JMML, which include the Raf/MEK/ERK and phosphoinositide-3′-OH kinase (PI3K)/Akt cascades. Mx1-Cre, Kras D12 and Mx1-Cre, Nf1 flox/ − mice accurately model many aspects of CMML and JMML. Treating Mx1-Cre, Kras D12 mice with GDC-0941 (also referred to as pictilisib), an orally bioavailable inhibitor of class I PI3K isoforms, reduced leukocytosis, anemia and splenomegaly while extending survival. However, GDC-0941 treatment attenuated activation of both PI3K/Akt and Raf/MEK/ERK pathways in primary hematopoietic cells, suggesting it could be acting through suppression of Raf/MEK/ERK signals. To interrogate the importance of the PI3K/Akt pathway specifically, we treated mice with the allosteric Akt inhibitor MK-2206. This compound had no effect on Raf/MEK/ERK signaling, yet it also induced robust hematologic responses in Kras and Nf1 mice with MPN. These data support investigating PI3K/Akt pathway inhibitors as a therapeutic strategy in JMML and CMML patients.
INTRODUCTION
Juvenile and chronic myelomonocytic leukemias (JMML and CMML) are aggressive myeloid malignancies characterized by monocytosis, splenomegaly, anemia and thrombocytopenia. 1 They are categorized as myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), a designation that reflects both expansion of myelomonocytic populations and aberrant multilineage differentiation, especially dyserythropoiesis and anemia. Chemotherapy has little benefit for MDS/MPN patients, and most die from their disease within 3 years. 2, 3 Hematopoietic growth and differentiation is deregulated in JMML and CMML as a result of mutations in KRAS, NRAS and in three genes that modulate the levels of active Ras-GTP (NF1, PTPN11 and CBL). [4] [5] [6] A promising therapeutic strategy for Ras-driven malignancies is to target the two downstream kinase effector pathways most frequently activated in cancer: Raf/MEK/ERK (or mitogenactivated protein kinase; MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt. Traditionally, Raf and PI3K have been viewed as parallel outputs of Ras. 7 However, PI3K can also be activated directly by growth factor receptors, and functions upstream of Ras in some cell types. 8, 9 Mouse models of JMML and CMML are valuable for characterizing disease mechanisms and testing new therapies. 6 Mx1-Cre, Kras LSL-D12 (hereafter designated Kras D12 ) mice harbor a conditional oncogenic Kras allele that is activated when Cre recombinase is expressed from the Mx1 promoter, which is itself induced by polyinosinic-polycytidylic acid. [10] [11] [12] These mice develop an aggressive and fully penetrant MDS/MPN that causes leukocytosis, splenomegaly, anemia and death by 10-16 weeks of age.
Mx1-Cre, Nf1
flox/ − mice (hereafter Nf1 Δ/ − ) undergo conditional loss of Nf1. These mice also develop MDS/MPN, but the disease is much more indolent and anemia is less prominent than in Kras D12 mice. We previously showed that the MEK inhibitor PD0325901 induced marked hematologic improvement in both Kras D12 and Nf1 Δ/− mice. 13, 14 These encouraging preclinical data provide evidence that signal-transduction therapy might be efficacious in JMML and CMML. However, the activity of PD0325901 in both models had some limitations. Importantly, treatment fails to reduce the proportion of Kras or Nf1 mutant bone marrow cells, and T-lineage acute lymphoblastic leukemia (T-ALL) emerged in some mice despite ongoing treatment. These data support investigating other Ras effector pathways as potential therapeutic targets. Recent data implicate aberrant PI3K signaling in JMML. [15] [16] [17] When activated by growth factor receptors or Ras-GTP, PI3K phosphorylates phosphatidylinositol (3,4)-bis-phosphate in the plasma membrane to create phosphatidylinositol (3,4,5)-tris-phosphate, which recruits and thereby activates a variety of downstream effectors. Akt is a serine/threonine kinase that becomes active when bound to phosphatidylinositol (3,4,5)-tris-phosphate via its PH domain and phosphorylated by the kinases PDK and mTORC2. Akt also has multiple effectors that regulate cell survival, growth, metabolism and differentiation.
Here, we test the importance of PI3K/Akt signaling in MDS/MPN using a pharmacologic approach in Kras D12 and Nf1 mouse models. We show that the class I PI3K inhibitor GDC-0941 improves hematologic function and prolongs survival in Kras D12 mice with MDS/MPN. Further corroborating the relevance of this pathway, the allosteric Akt inhibitor MK-2206 also induces substantial hematologic improvement in both Kras D12 and Nf1 mice. 18 Collectively, these studies support the idea that inhibitors targeting the PI3K/Akt pathway may have a role in the treatment of JMML or CMML.
MATERIALS AND METHODS Mice
Mice were maintained in the specific pathogen-free UCSF animal facility, and the institutional animal research committee approved all experimental procedures. Four-week-old F1 (129S4/Jae C57BL/6) Mx1-Cre, Kras mice and control littermates were injected intraperitoneally once with 250 μg of polyinosinic-polycytidylic acid (Sigma-Aldrich, St Louis, MO, USA) at weaning.
13 F1 (129X1/SvJ C57BL/6) Mx1-Cre, Nf1 flox/ − mice were injected intraperitoneally once with 500 μg of polyinosinic-polycytidylic acid 2 or 3 days after birth. Kras LSL-D12 allele burden was determined by quantitative PCR for the LSL cassette (see Supplementary Methods).
In vivo inhibitor studies GDC-0941 (Genentech, South San Francisco, CA, USA) was administered at the maximally tolerated dose of 125 mg/kg per day or 0.5% hydroxypropylmethylcellulose (Sigma-Aldrich; H9262)/0.2% Tween-80 vehicle by gavage once daily. MK-2206 (Proactive Molecular Research, Alachua, FL, USA) was given at 240 mg/kg in Captisol vehicle (Ligand Pharmaceuticals, La Jolla, CA, USA) by gavage every Monday, Wednesday and Friday. Treatment of Kras D12 mice began at 8-10 weeks of age, and treatment of Nf1 Δ/ − mice began at 6 months of age; in both cases, MDS/MPN was well established before therapy. Mice were removed from trial if moribund or severely anemic (hemoglobin (Hb) o6 g/dl). Blood counts were measured by Hemavet analyzer (Drew Scientific, Miami Lakes, FL, USA). Mice were randomly assigned to treatment groups without respect to sex; all experiments were unblinded.
Pharmacokinetics
Proteins were precipitated by the addition of acetonitrile (250 μl) containing losartan (0.5 μM) as internal standard, followed by vortexing and centrifugation. Supernatants (200 μl) were transferred to new low retention microcentrifuge tubes and dried under vacuum at 45°C. The dried samples were resuspended in 50 μl of 70/30 water/acetonitrile with vortexing and subsequently centrifuged for 5 min at 16 000 g at 4°C to remove insoluble material. The supernatants were transferred to a 96-well plate and samples were injected (10 μl) for PD0325901 and MK-2206 analysis. Both analytes were separated on an Agilent 1290 UPLC system (Agilent Technologies, Santa Clara, CA, USA) with a C18 column using a gradient run of 20-95% acetonitrile in water with 0.1% formic acid over 2 min at a flow rate of 0.4 ml/min and detected on an Agilent 6520 QTOF mass spectrometer (Agilent Technologies). Standard curves were generated from the area under the curve for standards within the quantifiable range. The lower limit of quantification was 30 nM for MK-2206 and 10 nM for PD0325901 in the plasma.
Flow cytometry
Antibodies (eBioscience, San Diego, CA, USA; BioLegend, San Diego, CA, USA; and BD Biosciences, San Jose, CA, USA) used: PE-Cy7 lineage markers ('Lin': CD3, CD4, CD5, CD8, B220, TER119, CD11b, Gr1), PacificBlue CD105, BV510 Sca1, FITC CD34, PE CD150, PerCP-Cy5.5 c-kit, APC CD48 and Alexa700 CD16/32. Intracellular phosphoproteins were analyzed as described. 13, 19 Data were collected on a LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo (FlowJo LLC, Ashland, OR, USA).
Progenitor assays
Bone marrow was incubated for 7 days in M3231 methylcellulose (StemCell Technologies, Vancouver, BC, Canada) with recombinant murine GM-CSF (granulocyte-macrophage colony-stimulating factor; PeproTech, Rocky Hill, NJ, USA) and/or inhibitors (GDC-0941 or MK-2206) in dimethyl sulfoxide (DMSO) 0.2%.
Statistics
Data were analyzed in Prism 6 (GraphPad, La Jolla, CA, USA) and R; 20 specific tests appear in figure legends. Linear mixed-effects modeling of blood counts over time is described in the Supplementary Methods. Sample sizes were based on prior preclinical studies. 13, 14 RESULTS PI3K inhibitor GDC-0941 suppresses MDS/MPN in Kras D12 mice GDC-0941 is a selective, ATP-competitive inhibitor of class I PI3K isoforms with favorable pharmacokinetic and pharmacodynamic properties that showed activity in preclinical models of breast and lung cancer. [21] [22] [23] [24] [25] We treated Kras D12 and control littermates with GDC-0941 or vehicle from the age of 6-8 weeks, when MDS/MPN is well established. The maximum daily dose of GDC-0941 tolerated in this background strain produces inhibitory concentrations in the bloodstream for 8 h. 26 As expected, this dose of GDC-0941 was generally well tolerated in control mice, which only showed modest weight loss (data not shown).
GDC-0941 treatment significantly extended the survival of Kras D12 mice and also improved peripheral blood cell counts (Figures 1a-c) . Anemia was largely prevented by GDC-0941 treatment, and leukocyte counts were reduced, although they remained above control values. Treatment also partially corrected splenomegaly in Kras D12 mice (Figure 1d ). Several Kras D12 mice treated with GDC-0941 died from T-ALL. This, along with incomplete correction of peripheral blood counts, suggested that GDC-0941 reduced the severity of MDS/MPN without eradicating Kras mutant cells. This was confirmed by demonstrating persistence of the Kras D12 allele in the active, recombined configuration in the blood of mice with a hematologic response to treatment (Figure 1e ).
We performed flow cytometry to assess the effects of GDC-0941 on early hematopoietic populations in bone marrow ( Figure 2 ). As expected from prior studies, 12, 13 Kras D12 mice had reduced numbers of phenotypic bone marrow HSC, which persisted with GDC-0941 treatment despite improvement in peripheral blood cell counts ( Figure 2a ). Hematopoiesis in Kras D12 mice is biased toward the granulocyte/monocyte lineage and away from megakaryocyte/erythroid differentiation. 10, 13, 19, 27 This lineage output bias is most apparent in skewing of the ratio of PreGM to PreMegE populations, which was partly corrected by GDC-0941 ( Figure 2b ). 28 We also examined the effects of GDC-0941 on the growth of myeloid progenitor colonies. Bone marrow harvested from Kras D12 mice after treatment with GDC-0941 for 5 weeks remained abnormal and demonstrated cytokine independence and GM-CSF hypersensitivity, which is a cellular hallmark of human JMML and murine Kras D12 progenitors (Figure 2c ). GDC-0941 suppressed myeloid colony formation in a dosedependent manner. However, Kras D12 and WT granulocytemacrophage colony-forming unit (CFU-GM) progenitors were equally sensitive to GDC-0941 in the presence of saturating levels of GM-CSF (Figure 2d ).
Akt inhibitor MK-2206 suppresses MDS/MPN in Kras
D12 mice PI3K inhibition attenuates MAPK signaling in primary hematopoietic cells because of complex 'upstream' effects on lipid signaling networks. 9 These data raised the possibility that hematologic improvement in response to GDC-0941 might be because of partial MAPK pathway inhibition. Furthermore, PI3K signals through effectors in addition to Akt. 29 Therefore, we asked if suppression of Akt signaling is sufficient to alleviate MDS/MPN initiated by endogenous Kras D12 expression. MK-2206 is an allosteric inhibitor that binds to the interface of the PH and kinase domains of Akt and does not inhibit any of 250 other kinases at 1 μM.
18,30,31
First, we verified that MK-2206 would inhibit Akt but not Raf/MEK/ERK signaling in myeloid progenitors. We used phosphospecific flow cytometry to analyze signal transduction in immature populations of bone marrow mononuclear cells that were exposed to signal-transduction inhibitors in vitro. Bone marrow was harvested from control and Kras D12 mice, briefly starved in the presence of inhibitors and then stimulated with a combination of stem cell factor (SCF) and GM-CSF. As expected, GDC-0941 strongly inhibited Akt phosphorylation (Figure 3a) and caused a modest but reproducible decrease in ERK phosphorylation. By contrast, MK-2206 inhibited Akt phosphorylation without affecting ERK. These data agree with our prior observations using structurally distinct PI3K inhibitors, and they are consistent with a model in which lipid second messengers downstream of PI3K regulate Raf/MEK/ERK signaling in myeloid progenitors. 9, 19 As expected, the potent and selective MEK inhibitor PD0325901 abrogated ERK phosphorylation, but did not alter Akt phosphorylation.
We next performed pharmacodynamic studies of MK-2206 by harvesting bone marrow from mice 24 h after drug administration, and immediately stimulating the marrow with SCF. Flow cytometry was used to assess Akt phosphorylation in progenitor cells, identified by the absence of mature lineage markers and expression of c-kit, the receptor for SCF. Although we did not observe target inhibition at a dose of 180 mg/kg, Akt phosphorylation was suppressed 24 h after doses of 240 and 360 mg/kg (Figure 3b ). Pharmacokinetic studies confirmed that MK-2206 persists in the blood for 424 h (Figure 3c ). Based on this long duration of action, mice were given MK-2206 three times each week. At this schedule, mice receiving 360 mg/kg had excessive weight loss, but those receiving 240 mg/kg demonstrated no overt toxicity. Kras D12 mice with MPN that received 240 mg/kg of MK-2206 had significantly increased survival, markedly improved blood cell counts and reduced splenomegaly (Figure 4) . Control mice remained well throughout treatment and maintained normal blood counts (Supplementary Figure 1) .
Combined inhibition of Akt and MEK
In contrast to GDC-0941, MK-2206 does not reduce Raf/MEK/ERK pathway activation. Therefore, MK-2206 and PD0325901 are likely to alleviate MDS/MPN through distinct biochemical mechanisms of action, and combining these agents might be more effective than using either alone. We developed a combined therapy regimen to test this hypothesis. While our single-agent studies of PD0325901 in Kras D12 and Nf1 Δ/ − mice administered 5 mg/kg per day, reducing the dose to 1.5 mg/kg per day inhibited MEK activity for at least 12 h and was efficacious in Nf1 and Kras mutant mice with MDS/MPN.
14 Importantly, because this lower dose of PD0325901 is better tolerated in combination with MK-2206 than 5 mg/kg (data not shown), we tested the efficacy of MK-2206 240 mg/kg thrice weekly with PD0325901 1.5 mg/kg daily in Kras D12 mice with MPN. We found no pharmacokinetic interaction between these two agents (Figure 3c ). Control mice exhibited no hematologic changes or any other overt toxicity from combined therapy. Combined MEK+Akt inhibition did not further improve in most hematologic parameters in Kras D12 mice, which were already largely corrected by either agent alone (Figure 4) . However, spleen size was smallest in mice receiving combination therapy (Figure 4e ).
Effects of MK-2206 on Kras
D12 hematopoietic progenitors
The frequency of HSC in the marrow was increased in Kras D12 mice receiving the combination of MK-2206 and PD0325901, and to a lesser extent in mice receiving either single agent (Figure 5a) . Furthermore, the myeloid to erythroid progenitor bias was corrected more by the combination than by either compound alone (Figure 5b ). Despite this improvement in bone marrow progenitor distributions, however, myeloid progenitors continued ×10 4 cells per culture) containing 0.01-10 ng/ml GM-CSF. Myeloid colony numbers were normalized to the saturating GM-CSF concentration to determine the dose-response curve. Mean ± s.e.m. are displayed for each data point; P = 0.0016 for Kras D12 GDC-0941 vs Kras D12 vehicle by permutation significance testing. 40, 41 (d) CFU-GM from untreated Kras D12 or control mice were grown in the presence of saturating GM-CSF (10 ng/ml) and 0.01-10 μM GDC-0941 or DMSO 0.2% (n = 3). Kras D12 does not alter the GDC-0941 dose-response curve in CFU-GM (analyzed by permutation significance testing).
to demonstrate an abnormal growth phenotype when cultured in vitro (Figure 5c ). CFU-GM grown from Kras D12 mice after 5 weeks of therapy with either MK-2206 or MK-2206+PD0325901 retained the abnormal, hypersensitive dose response to GM-CSF characteristic of MDS/MPN. This suggests that continuous drug treatment would be needed to maintain the clinical response to Akt and/or MEK inhibition. Finally, we asked whether expression of Kras D12 would influence the sensitivity of myeloid progenitors to D12 bone marrow cells. After harvest, cells were incubated with GDC-0941 (10 μM), the MEK inhibitor PD0325901 (10 μM; PD901), the Akt inhibitor MK-2206 (10 μM) or DMSO (0.001%) for 20 min before a 10 min stimulation with GM-CSF (10 ng/ml) and SCF (100 ng/ml). Lin − Kit+ CD34+ CD105 − myeloid progenitor cells are shown. Data from replicate experiments appear in the lower panels. Basal signal levels (white) and stimulated levels (black) are shown for each drug treatment. Fold change in median fluorescence intensity (MFI) is displayed. Data from five independent replicates on different days were analyzed using a linear model for MFI as predicted by stimulus, drug, replicate and the drug-stimulus interaction, with log transformation of MFI to correct heteroskedasticity. Asterisks indicate conditions in which the drug had a significant effect on the stimulated MFI, as indicated by the drug-stimulus interaction term (***P o0.001); this was not statistically significant (P40.05) where asterisks are not shown. MK-2206 in a colony assay. Bone marrow from untreated Kras D12 or control mice was cultured in methylcellulose containing MK-2206 over a range of 1-100 μM and a saturating concentration of GM-CSF (10 ng/ml). Kras D12 CFU-GM demonstrated a modestly increased sensitivity to MK-2206 as compared with controls.
MK-2206 suppresses MDS/MPN in
14,32 Homozygous Nf1 inactivation causes a subacute MDS/MPN with gradual onset of leukocytosis, splenomegaly, reticulocytosis and mild anemia beginning around 6 months of age, and death at 8-12 months. We treated Nf1 Δ/ − mice with MK-2206 to test whether Akt inhibition would also be effective in a less fulminant disease initiated by more subtle biochemical activation of Ras. Treatment with MK-2206 improved all aspects of the MDS/MPN phenotype in Nf1 Δ/ − mice, and the combination of PD0325901 and MK-2206 again yielded the biggest reduction in spleen size ( Figure 6 and Supplementary Figure S2) . These data are consistent with our observations in the Kras model.
DISCUSSION
This series of preclinical trials demonstrated that MDS/MPN driven by hyperactive Ras responds to inhibition of PI3K/Akt signaling. Together, these studies implicate aberrant signaling through PI3K and Akt in the pathogenesis of CMML and JMML. The improvement in Nf1 Δ/ − mice treated with MK-2206 demonstrates that this pathway remains important even when the disease is more indolent. Together with prior studies demonstrating efficacy of MEK inhibitors, MDS/MPN appears to follow a long-standing model whereby multiple effectors cooperate to mediate oncogenic signals downstream of Ras-GTP. 13, 14, 33, 34 Consistent with this idea, combined inhibition of MAPK and PI3K/Akt signaling yielded the best improvement in splenomegaly in both MDS/MPN models, and the most significant correction of bone marrow progenitor frequencies in Kras D12 mice. Our data complement recent studies by Gritsman et al., 17 who used a genetic strategy to ablate the p110α isoform of PI3K in the hematopoietic compartment. This delayed lethality but did not prevent the development of a JMML-like disease in Kras D12 mice. In contrast to this early, complete and permanent loss of a single PI3K isoform, treating mice with GDC-0941 at the maximally tolerated daily dose inhibits multiple PI3K isoforms for only~8 h, and we initiated treatment after MDS/MPN was well established. The robust response to GDC-0941 suggests that isoforms other than p110α are important in MDS/MPN, and no mice succumbed from MPN. This idea is consistent with studies showing that p110δ activity is required for MPN initiated by oncogenic SHP-2, a pleiotropic signal relay protein encoded by PTPN11 that functions upstream of Ras-GTP. 16 Furthermore, our studies of GDC-0941 demonstrate that a therapeutic index in MPN requires neither continuous nor isoform-selective inhibition of PI3K. A recent report from Staffas et al. 35 demonstrated that anemia and mortality in Kras D12 mice are influenced by non-hematopoietic tissues and identified blood loss from gastrointestinal neoplasia as a potential mechanism. However, in vitro and in vivo studies also show that oncogenic Ras has direct cell-intrinsic effects on erythropoiesis. [36] [37] [38] Therefore, both cell-intrinsic and cell-extrinsic factors underlie the anemia in Kras D12 mice, and PI3K/Akt inhibition in either hematopoietic or non-hematopoietic cells could explain improvement in anemia and mortality. Importantly, however, leukocytosis in Kras D12 mice is intrinsic to the hematopoietic system, and this is also corrected by PI3K/Akt pathway inhibition. Thus, the activity of these inhibitors cannot be mediated fully by effects on Kras D12 phenotypes outside the hematopoietic system. This idea is consistent with the concordant responses in Nf1 Δ/ − mice, which have milder extra-hematopoietic phenotypes. Finally, the differential effect of MK-2206 on Kras D12 myeloid progenitors grown in vitro also suggests some of the activity of MK-2206 acts in a cell-intrinsic manner ( Figure 5) .
Akt is one of many PI3K effectors that are activated by recruitment to phosphatidylinositol (3,4,5)-tris-phosphate in the plasma membrane. The efficacy of MK-2206 in the MDS/MPN models shows that Akt mediates an essential component of the PI3K signal in this disease. Akt, in turn, has 4100 substrates, including many with known relevance to hematopoiesis. Effectors such as mTOR, FOXO transcription factors, GSK3β, MDM2, NF-κB and BAD collectively regulate growth, metabolism, survival and fate decisions in hematopoietic cells. 39 Interestingly, our data suggest that beneficial and adverse effects of PI3K/Akt inhibition are mediated by distinct biochemical pathways. The maximally tolerated dose of GDC-0941 inhibits PI3K for only~8 h, whereas deep inhibition of Akt for 424 h is well tolerated. This suggests that toxicity may partly reflect loss of PI3K signals that are not dependent on Akt. The lipid second messengers that link PI3K to MEK in hematopoietic cells represent one example of an Akt-independent pathway that may contribute to the efficacy and/or toxicity of PI3K inhibition. 9 Many CMML patients suffer from chronic anemia, splenomegaly, transfusion dependence and iron overload, but are currently not eligible for hematopoietic stem cell transplantation because of risk of morbidity. 2 A therapy that reduces symptoms with minimal toxicity may have a role in the clinical management of this aggressive MDS/MPN. While HSCT is the standard of care for JMML, these vulnerable young patients might also benefit from treatment with MAPK and/or PI3K/Akt inhibitors to enhance hematopoiesis and improve their overall clinical condition before undergoing transplantation. Our preclinical data suggest that this can be achieved by targeting either Raf/MEK/ERK or PI3K/Akt signaling. The experiments presented here also implicate Akt as a potential effector of PI3K that could be targeted in MDS/MPN. This is significant, since having multiple targets for therapy would allow risks and benefits to be more closely tailored to individual patients, and may also enable combination therapy.
Importantly, however, T-ALL emerges during treatment with any signal-transduction inhibitor used to treat Kras D12 mice: PD0325901, GDC-0941, MK-2206 or PD325901+MK-2206. These data suggest there is a high probability that mutant HSC will ultimately acquire cooperating mutations that enable them to overcome these targeted agents. Given this, developing drugs or drug combinations capable of eradicating mutant HSC remains a fundamental challenge in JMML and CMML. or control mice were grown in the presence of saturating GM-CSF (10 ng/ml) and 1-100 μM MK-2206 or DMSO 0.2% (n = 4). Colony numbers were normalized to DMSO control; mean ± s.e.m. are displayed. CFU-GM from Kras D12 mice were more sensitive to MK-2206 (P = 0.029 by permutation significance testing). 
